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Abstract The eukaryotic transcription factor NF-gB is acti- 
vated by a large variety of stimuli. We have recently shown that 
ER stress, caused by an aberrant accumulation of membrane 
proteins within this organdie, also activates NF-gB. Here, we 
show that activation of NF-gB by ER stress requires an increase 
in the intracellular levels of both reactive oxygen intermediates 
(ROIs) and Ca 2+. Two distinct intracellular Ca z+ chelators and a 
panel of structurally unrelated antioxidants prevented NF-gB 
activation by various ER stress-eliciting agents, whereas only 
antioxidants but not the Ca 2+ chelators prevented NF-gB 
activation by the inflammatory cytokine TNF-c¢. Consistent 
with an involvement of calcium, the ER-resident Ca2+-ATPase 
inhihitors thapsigargin and cyclopiazonic acid (CPA), which 
trigger a rapid efflux of Ca 2+ from the ER, also potently 
activated NF-gB. Pretreatment with a Ca 2+ chelator abrogated 
this induction. The Ca 2+ chelator BAPTA-AM inhibited ROI 
formation in response to thapsigargin and CPA treatment, 
suggesting that the Ca 2+ increase preceded ROI formation 
during NF-gB activation. The selective inhibitory effect of the 
drug tepoxalin suggests that the peroxidase activity of cyclooxy- 
genases or lipoxygenases was responsible for the increased ROI 
production in response to Ca 2+ release by thapsigargin. 
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1. Introduction 
The eukaryotic transcription factor NF-~B is a central med- 
iator of the immune response. As such, it is activated by a 
large variety of pathological stimuli including bacterial lipo- 
p,lysaccharide, viral proteins and inflammatory cytokines (for 
a review see [1]). Since these agents activate many diverse 
signal transduction pathways and second messenger systems, 
N F-~B must either be activated by several mechanisms or the 
w rious pathways must converge at one point to elicit a pro- 
t~typic NF-~B-activating reaction. 
In most cells, NF-~B is cytoplasmically retained in an in- 
at tive complex by binding to an inhibitory subunit, called I~:B 
[2 I. All NF-~B-inducing stimuli characterized to date cause 
the phosphorylation and subsequent degradation of I~B-~, 
thereby releasing active NF-~B. This consists of a heterodimer 
o members of the NF-KB/Rel family of transcription factors, 
n:~ost often p50 and p65 (RelA). Activated NF-rB rapidly 
tr mslocates to the nucleus where it induces transcription of 
target genes, such as cytokines, immunoreceptors and adhe- 
sion molecules (for a detailed list see [1]). Both I~B-tx phos- 
pimrylation and degradation are prevented by a large variety 
*t ~orresponding author. Fax: (49) (761) 206 1599. 
0{!14-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. 
P,'I SO0 1 4 -5793(96)00800-9  
of structurally unrelated antioxidants [3-8]. Moreover, micro- 
molar concentrations of H202 lead to NF-~:B activation in 
some cell lines. Based on these observations, it was proposed 
that reactive oxygen intermediates (ROIs) serve as common 
second messengers in many NF-~B-activating conditions [9]. 
The precise signal transduction pathways leading to RO! 
production and subsequent NF-~B activation remain un- 
known for many stimuli. However, in a number of cases, 
the enzymes responsible for ROI production have been iden- 
tified. TNF-mediated NF-~B activation in L929 cells requires 
an intact mitochondrial electron transport chain since addi- 
tion of the complex I inhibitor rotenone or elimination of 
mitochondria blocks NF-~:B activation by this cytokine [10]. 
In contrast, the complex III inhibitor antimycin A, which 
potentiates ROI production augmented NF-~cB induction. It 
was proposed that mitochondrial ubiquinone generates the 
NF-~:B-activating ROIs in response to TNF stimulation. Trig- 
gering of the CD28 receptor on T cells also results in the 
production of ROIs and NF-~B activation [11]. Inhibitors 
of 5-1ipoxygenase block NF-~B activation by CD28, suggest- 
ing that this enzyme generates the ROIs in this pathway. 
Overexpression of the ROI-producing enzyme cyclooxygen- 
ase-1 was found to augment NF-~B induction by phorbol 
ester. This effect was dependent on the enzyme's peroxidase 
activity [12] 
We have recently shown that NF-~:B is activated by a vari- 
ety of agents which perturb ER function [13]. Since ER stress 
activates NF-KB-dependent nuclear gene expression, a novel 
ER-nuclear signal transduction pathway could be defined. 
This pathway is pharmacologically distinct from the pre- 
viously characterized unfolded protein response pathway. 
Using mutants of the adenovirus protein E3/19K we have 
identified the NF-~B-activating signal as the retention and 
subsequent accumulation of proteins in the ER, a condition 
we have termed ER overload [14]. 
Since the inactive NF-~B resides in the cytoplasm, ER over- 
load must emit a signal that reaches NF-~B in the cytosol. We 
show here that both the efflux of Ca 2+ from the ER and the 
subsequent generation of ROIs are required for ER overload- 
mediated NF-~cB activation. NF-~B induction by ER stress is 
prevented by pre-incubation of cells with the intracellular 
Ca 2+ chelators BAPTA-AM and TMB-8. Moreover, inhibi- 
tion of the ER-resident Ca2+-ATPase by thapsigargin or 
CPA, which causes rapid efflux of Ca 2+ from the ER, potently 
induced NF-~:B. This activation was blocked by BAPTA-AM. 
Antioxidants prevented NF-~cB induction both in response to 
ER stress and thapsigargin or CPA stimulation, suggesting 
that ROIs are also required for NF-~B-mediated ER-nuclear 
signal transduction. Incubation of cells with BAPTA-AM in- 
hibits ROI production following thapsigargin or CPA stimu- 
lation, suggesting that Ca 2+ release precedes ROI formation 
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in the NF-~:B-mediated ER-nuclear signal transduction path- 
way. 
2. Materials and methods 
2.1. Cell culture and transfections 
HeLa cells (ATCC no. CCL 2) and 293 cells (ATCC no. CRL 1573) 
were grown in Dulbecco's Modified Eagle Medium supplemented with 
10% fetal calf serum and 50 ~tg/ml penicillin-streptomycin (all from 
Gibco-BRL). HeLa and 293 cells were plated 12-16 h prior to trans- 
fection at a density of 106 cells per 60 mm dish. Transfections were 
performed using calcium phosphate precipitation as previously de- 
scribed [15]. The amounts of plasmids used are indicated in the figure 
legends. Tunicamycin, brefeldin A, 2-deoxyglucose, TPA, thapsigar- 
gin, N-acetyl-L-cysteine (NAC), butylated hydroxyanisole (BHA), ro- 
tenone, nordihydroguaiaretic a id (NDGA), dithoithreitol (DTT), 
pyrrolidine dithiocarbamate (PDTC), metyrapone, allopurinol, 
hydroxyurea, curcumin and indomethacin were purchased from Sigma 
Biochemicals. Cyclopiazonic acid, TMB-8 and 5,8,11,14-eicosatetray- 
noic acid (ETYA) were purchased from Calbiochem. The protein 
kinase C inhibitor bisindolylmaleimide was purchased from Boehrin- 
ger Mannheim. BAPTA-AM was obtained from Molecular Probes. 
Tepoxalin was generously donated by Dr. T. Parks, Boehringer In- 
gelheim, Inc. TNF was a kind gift from Prof. Karl Decker, Freiburg. 
2.2. Plasmids 
The hemagglutinin expression vector contains the entire HA coding 
sequence of the influenza virus strain A/FPV/Rostock/34 (H7N1) 
cloned into the vaccinia virus insertion vector pSC11 and was a gen- 
erous gift from Drs. W. Garten and H. Klenk (University of Mar- 
burg). The I.t chain expression plasmid was a kind gift from Dr. M. 
Reth (Max Planck Institute, Freiburg). The E3/19K vector contains 
the EcoRI D fragment of adenovirus 2 in the pBluescript II KS vector 
[16]. The MHC class I K d expression vector has been described else- 
where [17]. Both were kindly provided by Dr. H.-G. Burgert, Max 
Planck Institute, Freiburg. 
2.3. Electrophoretic mobility shift assays 
Total cell extracts were prepared using a high-salt detergent buffer 
(Totex) (20 mM HEPES, pH 7.9, 350 mM NaCI, 20% (w/v) glycerol, 
1% (w/v) NP-40, 1 mM MgC12, 0.5 mM EDTA, 0.1 mM EGTA, 0.5 
mM DTT, 0.1% PMSF, 1% aprotinin). Cells were harvested by cen- 
trifugation, washed once in ice-cold PBS (Sigma) and resuspended in 
four cell volumes of Totex buffer. The cell lysate was incubated on ice 
for 30 min, then centrifuged for 5 min at 13000xg at 4°C. The 
protein content of the supernatant was determined and equal amounts 
of protein (10-20 ~g) added to a reaction mixture containing 20 ~g 
BSA (Sigma), 2 I.tg poly(dI-dC) (Boehringer), 2 t.tl buffer D+ (20 mM 
HEPES, pH 7.9; 20% glycerin, 100 mM KC1, 0.5 mM EDTA, 0.25% 
NP-40, 2 mM DTT, 0.1% PMSF), 4 I11 buffer F (20% Ficoll 400, 100 
mM HEPES, 300 mM KC1, 10 mM DTT, 0.1% PMSF) and 100000 
cpm (Cerenkov) of a z2p-labeled oligonucleotide in a final volume of 
20 I.tl. Samples were incubated at room temperature for 25 min. Re- 
actions for AP-1 contained 5 mM MgCI2 in addition. NF-r,B and AP- 
1 oligonucleotides (Promega) were labeled using ~[32p]ATP (3000 Ci/ 
mmol; Amersham) and T4 polynucleotide kinase (Fermentas). 
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2.4. FACS analysis 
Cells (1 x 106) were washed three times in phosphate-buffered saline 
(PBS) and harvested in PBS. DCFH diacetate (Fluka) was added to a 
final concentration of 5 ~tM and cells incubated at 37°C for 10 min. 
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Fig. 1. Effect of Ca 2+ chelators on NF-~B activation by 2-deoxyglu- 
cose and TNF. (A) HeLa cells were pretreated for 1 h with the indi- 
cated concentrations of TMB-8 (lanes 3-5) and BAPTA-AM (lanes 
6,7). Subsequently, cells were stimulated with 30 mg/ml 2-deoxyglu- 
cose for 4 h (lanes 2-7). Unstimulated control cells are shown in 
lane 1. (B) Cells were pretreated with the same concentrations of
TMB-8 and BAPTA-AM as in A, but then stimulated with 200 U/ 
ml TNF for 1 h (lanes 2-7). Unstimulated control cells are again 
shown in lane 1. Total cell extracts were prepared and assayed in 
an EMSA using a high-affinity ~B-binding site as a probe. A filled 
arrowhead indicates pecific NF-r~B complexes. The open circle de- 
notes non-specific binding to the probe and the open arrowhead 
shows unbound oligonucleotide. 1 2 3 4 5 6 
< 
7 
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Cells were scanned on a FACSSORT flow cytometer (Becton Dick- 
in,on) with excitation and emission settings at 495 and 525 nm, re- 
spectively. The results were analyzed with the Lysis II software pro- 
gramm. 
3. Results 
3 1. Ca 2+ chelators abrogate NF-r,B activation by 
2-deoxyglucose but not TNF-ct 
We investigated the effect of the intracellular Ca 2+ chelators 
B~PTA-AM and TMB-8 on the activation of NF-~zB by 2- 
d~,'oxyglucose, an inhibitor of N-glycosylation which elicits ER 
sl tess. Previously, we have shown that NF-~B activation by 
[ R stress follows slow kinetics, most likely due to the gradual 
a,:cumulation of protein within the ER [13], with maximal 
artivation seen after 24 h. However, since Ca 2+ chelators 
nay not retain their activity over such a long period of 
t~ he, HeLa cells were treated with 30 mg/ml 2-deoxyglucose 
fi ,r only 4 h after a preincubation of 1 h with various con- 
c~.~ntrations f the chelators. Thereafter, total cell extracts were 
p "epared and assayed for NF-KB DNA binding activity using 
eLectrophoretic mobility shift assays (EMSA). Incubation of 
[i eLa cells with 2-deoxyglucose for 4 h led to significant but 
s tb-maximal NF-~B activation (Fig. 1A, lane 2). Pretreat- 
n ent of cells with two different Ca 2+ chelators prevented 
lX F-~zB activation by 2-deoxyglucose (Fig. 1A, lanes 3-7), 
s~tggesting that an increase in intracellular Ca 2+ was required 
f, ,r NF-~cB induction by the N-glycosylation i hibitor. 
We tested whether BAPTA-AM and TMB-8 could also 
a t'ect NF-~cB activation by TNF-c~. HeLa cells were pre- 
teated for 1 h with the same concentrations of BAPTA- 
A M and TMB-8 used in the previous experiment, afterwards, 
c:lls were stimulated with 200 IU/ml TNF for 1 h. TNF 
s rongly induced NF-~B DNA binding activity in HeLa cells 
(!:ig. 1B, lane 2). In contrast to 2-deoxyglucose-mediated NF- 
KB activation, pretreatment with Ca 2+ chelators did not sig- 
r~ ficantly influence NF-~B activation by TNF (Fig. 1B, lanes 
3 -7). 
5 2. Calcium chelators interfere with many ER stress-inducing 
conditions 
In order to determine whether Ca 2+ chelators also inhibit 
I',F-~B activation in response to other ER stress-inducing 
compounds, HeLa cells were preincubated with 40 ~tM BAP- 
q A-AM for 1 h and then stimulated with 50 ~tg/ml tunicamy- 
cn, 30 mg/ml 2-deoxyglucose, 250 ~tg/ml brefeldin A, 5 ~tM 
t tapsigargin or 15 ~tM CPA for 4 h. Again, activation by 
t~ese agents is sub-maximal due to the short treatment time. 
1'. F-~cB activation by all these agents is inhibited by pretreat- 
tent with the Ca 2+ chelator (Fig. 2), indicating that Ca 2+ is 
r ;quired as a messenger for NF-~cB activation by a number of 
s~ructurally and mechanistically unrelated ER stress-eliciting 
compounds. 
ER stress can also be elicited by the expression of integral 
tembrane proteins which accumulate in the ER [13]. We have 
previously shown that the overexpression f influenza virus 
hemagglutinin [18], adenovirus E3/19K [14], immunoglobulin 
heavy chain [18] and MHC class I [14] causes NF-~B activa- 
t on by ER overload. Here, we investigated the effect of the 
( a 2+ chelator TMB-8 on NF-KB activation by overexpression 
e, f these proteins. 293 cells were pretreated for 1 h with 1 mM 
q-MB-8, which does not interfere with the DNA transfection 
,¢  
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Fig. 2. Pretreatment with the Ca 2+ chelator BAPTA-AM abrogates 
NF-~cB activation by ER stress-inducing a ents. HeLa cells were in- 
cubated with 40 pM BAPTA-AM for 1 h (lanes 3,5,7,9,11) or left 
untreated (lanes 2,4,6,8,10), after which they were stimulated with 
50 ~tg/ml tunicamycin (lanes 2,3), 30 mg/ml 2-deoxyglucose (lanes 
4,5), 250 I.tg/ml brefeldin A (lanes 6,7), 5 IxM thapsigargin (lanes 
8,9) or 15 /.tM CPA (lanes 10,11) for 4 h. Total cell extracts were 
prepared and assayed in an EMSA using a high-affinity ~B-binding 
site as a probe. A filled arrowhead indicates pecific NF-rB com- 
plexes. The open circle denotes non-specific binding to the probe 
and the open arrowhead shows unbound oligonucleotide. 
procedure, subsequent protein expression or TNF-mediated 
NF-~B activation [14]. Subsequently, cells were transfected 
with 6 [tg of expression vectors for the various proteins. 4 h 
after transfection, total cell extracts were prepared and as- 
sayed for NF-~cB DNA binding activity. The NF-~B activa- 
tion induced by expression of all four proteins was inhibited 
by the Ca 2~ chelator TMB-8 (Fig. 3). Thus, ER stress caused 
by both drugs and protein overexpression requires an increase 
in intracellular Ca 2+ for activation of transcription factor NF- 
~B. 
3.3. NF-r,~B activation by ER stress does not require protein 
kinase C 
An increase in intracellular calcium may activate Ca2+/ 
phospholipid-dependent protein kinase C isozymes. More- 
over, the Ca 2+ chelator TMB-8 has been reported to have 
effects on phospholipid metabolism and protein kinase C 
[19]. We therefore assessed whether activation of protein ki- 
nase C played a role in ER stress-mediated NF-~B activation. 
293 cells were pretreated for 1 h with various concentrations 
of the PKC inhibitor bisindolylmaleimide [20] and subse- 
quently either transfected with 6 Ixg of E3/19K expression 
plasmid (Fig. 4A,B, lanes 2-5), stimulated with 200 IU/ml 
of TNF (lanes 6-9), or with 50 ng/ml of the active phorbol 
ester phorbol 12-myristate 13-acetate (TPA) (lanes 10-13). 
Transfected cells were harvested after 4 h, stimulated cells 
after 1 h. Total cell extracts were prepared and assayed for 
DNA binding activities of both transcription factors NF-~B 
(Fig. 4A) and AP-1 (Fig. 4B). Neither E3/19K-mediated nor 
TNF-stimulated NF-~B activation was altered by the protein 
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Fig. 3. The Ca 2+ chelator TMB-8 prevents NF-~B activation by ER 
overload. 293 cells were pretreated for 1 h with 1 mM TMB-8 
(lanes 3,5,7,9) or left untreated (lanes 2,4,6,8). Cells were then tran- 
siently transfected with 6 lag of either a influenza haemagglutinin ex-
pression vector (lanes 2,3), an E3/19K expression vector (lanes 4,5), 
a immunoglobulin ~t-heavy chain expression vector (lanes 6,7) or an 
expression vector for MHC class I (lanes 8,9). 4 h after transfection 
total cell extracts were prepared and assayed for NF-nB DNA bind- 
ing in an EMSA. A filled arrowhead indicates pecific NF-nB com- 
plexes, the open circle denotes non-specific binding to the probe and 
the open arrowhead shows unbound oligonucleotide. 
kinase C inhibitor treatment (Fig. 4A, lanes 2-9). In contrast, 
the induction of AP-1 by TPA, which involves protein kinase 
C [21], was completely inhibited by 0.5 ~tM bisindolylmalei- 
mide (Fig. 4B, lanes 10-13). E3/19K-mediated AP-1 activation 
was also sensitive toward PKC inhibition (Fig. 4B, lanes 6-9). 
In 293 cells, TPA did not induce NF-~cB and TNF did not 
stimulate AP-1 (Fig. 4A, lane 10; Fig. 4B, lane 6). The results 
provide pharmacological evidence that NF-nB activation by 
ER overload is independent of protein kinase C. 
3.4. Antioxidants prevent NF-rd~ activation by ER overload 
It has been suggested that ROIs serve as common messen- 
ger for many NF-~cB activating stimuli [9]. We therefore used 
a panel of structurally unrelated antioxidants o investigate 
the role of ROIs in NF-~:B activation by ER overload. 293 
cells were pretreated for 1 h with 30 mM N-acetyl-L-cysteine 
(NAC), 250 txM butylated hydroxyanisole (BHA), 5 ~tM ro- 
tenone, 40 IxM nordihydroguaiaretic acid (NDGA), 100 ~tM 
pyrrolidine dithiocarbamate (PDTC) or 5 mM dithiothreitol 
(DTT). Subsequently, cells were transfected with 6 ~tg of E3/ 
19K expression vector. Total cell extracts were prepared 4 h 
after transfection and analyzed for NF-~B DNA binding. All 
six antioxidants more or less strongly interfered with E3/19K- 
induced NF-~B activation (Fig. 5). The effect of PDTC is less 
pronounced because this compound oes not retain its anti- 
oxidative activity over 4 h. Immunoprecipitations revealed 
that, with the exception of PDTC, these antioxidants did 
not interfere with transfection or E3 protein expression in 
these cells (data not shown). PDTC inhibited E3/19K expres- 
sion by approx. 50%. Taken together, these data suggest that 
ROIs also play a role as messenger molecules in ER overload- 
mediated NF-~B activation. 
3.5. Inhibition of ER-resident Ca2+-ATPase induces oxidative 
stress and NF-r~B activation 
The compounds thapsigargin and CPA inhibit the ER-res- 
ident Ca2+-ATPase, thereby causing a rapid effiux of Ca 2+ 
from the ER lumen into the cytoplasm [22]. In contrast o 
ER stress-eliciting a ents, such as 2-deoxyglucose, which act 
slowly [13], thapsigargin and CPA activate NF-~B with rapid 
kinetics, maximal activation occurring after 1 h of stimulation 
[14]. We therefore investigated whether these agents also re- 
quire ROIs to activate NF-~B. This may indicate whether an 
increase in calcium precedes the generation of ROIs. HeLa 
cells were pretreated for 1 h with 100 ~tM of the antioxidant 
PDTC before stimulation with either 5 I.tM thapsigargin, 15 
~tM CPA or 50 ng/ml TPA. The antioxidant inhibited NF-xB 
activation by all three stimuli (Fig. 6), suggesting that the 
thapsigargin and CPA-induced Ca z+ release causes the pro- 
duction of ROIs which ultimately mediate NF-~B activation. 
3.6. Tepoxalin inhibits NF-~,B activation by thapsigargin but 
not by TPA or TNF 
We tried to identify pharmacologically the enzyme respon- 
sible for ROI production in response to calcium increase by 
thapsigargin. To this end, HeLa cells were treated with inhib- 
itors for a variety of ROI-producing enzymes and assayed for 
A Probe: ~B 
Trutm. t :  I - - I  ES/19K I TNF 
PKClnhlbltor:l 0 i 0 0.5 1 5 l0  0.5 1 
I TPA ] 
510 , 51 
B Probe: AP-1 
Treatment: I - - I  E3/19K I TNF I TPA 
PKCInhlbitor: I 0 I 0 0.5 1 5 I 0 0.5 1 510  0.5 1 
I 
51 
Fig. 4. E3/19K-induced NF-~B activation does not require protein 
kinase C. 293 cells were pretreated for 1 h with 0.5, 1 or 5 ~tM bis- 
indolylmateimide as indicated and subsequently either transfected 
with 6 lag of E3/19K expression plasmid (lanes 2-5), stimulated with 
200 U/ml of TNF (lanes 6-9), or treated with 50 ng/ml TPA (lanes 
10-13). Transfected cells were harvested after 4 h, stimulated cells 
after 1 h. Total cell extracts were prepared and assayed for DNA 
binding of both transcription factors NF-~B (A) and AP-1 (B). Sec- 
tions of fluorograms are shown. A filled arrowhead indicates specific 
NF-~B (A) or AP-1 (B) complexes and the open circles denote non- 
specific binding to the probes. 
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thapsigargin-induced NF-~B activation (Fig. 7). Neither the 
xanthine oxidase inhibitor allopurinol, nor the ribonucleotide 
rcductase inhibitor hydroxyurea had any effect on the induc- 
tion of NF-~B by thapsigargin (lanes 6-11). The P450 inhi- 
bitor metyrapone and the cyclooxygenase inhibitor indo- 
n'~ethacin slightly reduced NF-KB activation, but only at 
very high concentrations, (lanes 5,17). However, these high 
d ~ses far exceeded the IC50 required for enzyme inhibition 
i] intact cells and, therefore, most likely reflected nonspecific 
effects of the compounds. Curcumin, an inhibitor of the lipox- 
;enase pathway [23], inhibited NF4cB activation at very low 
c.mcentrations (20 gM, lane 12). However, this inhibition may 
l~: caused by curcumin's potent antioxidative potential [24]. 
We thus tested the lipoxygenase and cyclooxygenase inhibitor 
I TYA, an arachidonate analogue, for its ability to inhibit 
/',F-loB activation by thapsigargin. At concentrations up to 
3 )0 gM, ETYA was unable to inhibit NF-~B induction (lanes 
l ~-20). However, a second lipoxygenase and cyclooxygenase 
i~thibitor, tepoxalin that specifically targets the intrinsic per- 
c, xidase activity of the enzymes [25], inhibited thapsigargin- 
r Lediated NF-~cB activation at gM concentrations (Fig. 8, 
lnes  2-5). Tepoxalin had no effect on TPA- or TNF-  
r tediated NF-~cB activation (lanes 6 13). This suggests that 
Treatment: 
T rensfectlon: I - - I  
Q 
 eo/e,o.Oe 
E3/19K I 
0 
<] 
1 2 3 4 5 6 7 8 
]ig. 5. E3/19K-mediated NF4cB activation is inhibited by various 
s ructurally unrelated antioxidants. 293 cells were left untreated 
(lanes 1,2) or treated for 1 h with 30 mM N-acetyl-u-cyteine (NAC, 
lane 3), 250 gM butylated hydroxyanisole (BHA, lane 4), 5 gM ro- 
t,:none (lane 5), 40 gM nordihydroguaiaretic acid (NDGA, lane 6), 
100 I.tM pyrrolidine dithiocarbamate (PDTC, lane 7) or 5 mM 
dithiothreitol (DTT, lane 8). Subsequently, cells were transfected 
with 6 gg of E3/19K expression vector (lanes 2-8). 4 h after trans- 
tection total cell extracts were prepared and assayed for NF-lcB 
DNA binding in an EMSA. A filled arrowhead indicates pecific 
NF-lcB complexes, the open circle denotes non-specific binding to 
lhe probe and the open arrowhead shows unbound oligonucleotide. 
Inducer: 
Inhibitor: I - I -  o 1-  o1- Ol 
a o ix ix ix 
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Fig. 6. NF4cB activation by inhibitors of the ER resident Ca 2+- 
ATPase is inhibited by the antioxidant PDTC. HeLa cells were pre- 
treated for 1 h with 100 gM PDTC (lanes 3,5,7) or left untreated 
(lanes 1,2,4,6). Cells were then stimulated with 5 gM thapsigargin 
(lanes 2,3), 15 p.M CPA (lanes 4,5) or 50 ng/ml TPA (lanes 6,7) for 
1 h. Total cell extracts were prepared and assayed for NF-~cB DNA 
binding in an EMSA. A filled arrowhead indicates specific NF-)cB 
complexes. The open circle denotes non-specific binding to the 
probe and the open arrowhead shows unbound oligonucleotide. 
the peroxidase activity within cxclooxygenases or lipooxy- 
genases may be responsible for generating ROIs in response 
to increased intracellular calcium levels. 
3. 7. Ca 2+ release precedes ROI  generation during thapsigargin 
and CPA treatment 
So far, we have provided pharmacological evidence that ER 
stress-mediated NF-~cB activation requires both Ca 2+ release 
from the ER as well as the production of ROIs. However, it is 
not clear which of the two events comes first and whether one 
is a consequence of the other. We have addressed this ques- 
tion by investigating the effect of Ca 2+ chelators, Ca2+-ATP - 
ase inhibitors and antioxidants on the intracellular production 
of ROIs as determined by flow cytometry using the fluorescent 
dye DFCH [26]. HeLa cells were preincubated for 1 h with 30 
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Fig. 7. Effect of various inhibitors of ROI producing enzymes on NF-nB activation by thapsigargin. HeLa cells were treated for 1 h with the 
p450 inhibitor metyrapone (lanes 3-5), the xanthine oxidase inhibitor allopurinol (lanes 68), the ribonucleotide r ductase inhibitor hydroxyurea 
(lanes 9-11), curcumin, an inhibitor of the lipoxygenase pathway (lanes 12 14), the cyclooxygenase inhibitor indomethacin (lanes 15 17) or the 
lipoygenase and cyclooxygenase inhibitor ETYA, an arachidonate analogue (lanes 18 20), at the indicated concentrations. Afterwards, cells 
were stimulated for 1 h with 15 gM thapsigargin. Total cell extracts were prepared and assayed for NF-r,B DNA binding in an EMSA. A filled 
arrowhead indicates pecific NF-r,B complexes. The open circle denotes non-specific binding to the probe and the open arrowhead shows un- 
bound oligonucleotide. 
gM of the Ca 2+ chelator BAPTA-AM or 100 gM of the 
antioxidant PDTC. Cells were then stimulated with either 
250 gM H202, 5 gM thapsigargin or 15 gM CPA for 1 h. 
Cells were then incubated with 5 gM DCFH for 10 min at 
37°C and analyzed for ROI production by flow cytometry. As 
expected, treatment with H202 induces oxidative stress, which 
is reflected in a significant increase in mean fluorescence (Fig. 
9). Thapsigargin and CPA treatment also increased the ROI 
production of HeLa cells showing that inhibition of Ca ~+- 
ATPase, i.e. Ca 2+ efltux from the ER, causes oxidative stress. 
The antioxidant PDTC decreased intracellular ROI produc- 
tion in response to added H202, thapsigargin and CPA (Fig. 
9). Interestingly, the Ca 2+ chelator BAPTA-AM also reduced 
ROI content in response to all three stimuli (Fig. 9). In addi- 
tion, both PDTC and BAPTA-AM lowered the basal evel of 
ROIs in unstimulated HeLa cells. Of note, its chemical struc- 
ture does not predict BAPTA-AM to have any antioxidative 
potential. These data show that the release of Ca 2+ from the 
ER by inhibition of the ER-resident Ca2+-ATPase leads to 
oxidative stress in HeLa cells and that this can be prevented 
by incubation with a Ca 2+ chelator. Moreover, they suggest 
that Ca 2+ release precedes the production of ROIs during ER 
stress. 
4. Discussion 
The disruption of ER function represents a severe stress to 
cells. This can occur during viral infection or the exposure to 
xenobiotics. We have previously shown that cells can respond 
to ER stress by inducing the transcription factor NF-nB [13]. 
Since active NF-KB translocates directly to the nucleus and 
induces gene transcription, this established a novel signal 
transduction pathway between the ER and the cell nucleus 
[13]. In the present study, we wished to determine the second 
messenger molecules which mediate the activation of NF-nB 
by ER stress. The observation that inhibition of the ER-resi- 
dent Ca2+-ATPase, which causes rapid release of Ca 2+ from 
the organelle, potently activates NF-~:B, suggested that Ca 2+ 
release may mediate NF-~cB activation by ER stress. We show 
here that two structurally unrelated Ca 2+ chelators inhibit 
NF-~cB activation in response to various ER stress inducing 
conditions. These include the inhibition of N-glycosylation 
(tunicamycin and 2-deoxyglucose), ER-Golgi fusion (brefeldin 
A), inhibition of the ER-resident Ca2+-ATPase (thapsigargin 
and CPA) as well as the overexpression f four different pro- 
teins which are known to accumulate in the ER (Fig. 3). It 
therefore appears that the release of Ca 2+ from the ER repre- 
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Fg. 8. The lipoxygenase and cyclooxygenase inhibitor tepoxalin pre- 
vt.nts NF-nB activation by thapsigargin, but not by TPA or TNF. 
H,.'La cells were preincubated for 1 h with various concentrations of 
tel~oxalin as indicated. Subsequently, cells were stimulated with 15 
btM thapsigargin (lanes 2-5), 50 ng/ml TPA (lanes 6-9) or 200 U/ml 
T~IF (lanes 10-13) for 1 h. Total cell extracts were prepared and as- 
saced for NF-nB DNA binding in an EMSA. A filled arrowhead in- 
di,mtes pecific NF-nB complexes. The open circle denotes non-spe- 
cific binding to the probe and the open arrowhead shows unbound 
ol gonucleotide. 
scnts a general mechanism by which NF-~B is activated in 
response to ER stress. 
With the exception of T lymphoid cells, Ca ~+ has not been 
p: eviously implicated as a messenger in NF-~cB activation. In 
"I cells, calcium ionophores are fairly weak activators of NF- 
~1~ on their own, however, they strongly synergize with phor- 
b. ~1 esters [27]. In HeLa cells, calcium ionophores do not sig- 
n ficantly induce NF-~B (data not shown). Activation of NF- 
~1~ by TNF  is not affected by pretreatment of HeLa (Fig. 1B) 
o 293 cells (data not shown) with Ca 2+ chelators. These data 
p~eclude that TMB-8 or BAPTA-AM are exhibiting a pre- 
v ously unrecognized antioxidative capacity. In addition, the 
sl:'ucture of these Ca 2+ chelators does not suggest hat they 
p ~ssess antioxidative properties. 
We show that, in addition to Ca 2+, the generation of ROIs 
is required to activate NF-nB in response to ER stress. More- 
o'er,  Ca 2+ release from the ER causes oxidative stress in 
Iq eLa cells, which can be abrogated by pretreatment with a 
( i  2+ chelator. The observed decrease in steady state ROI 
le eels in HeLa cells following treatment with BAPTA-AM 
(t 'ig. 9) suggests that the intracellular Ca 2+ concentration 
rrodulates ROI homeostasis. An interrelationship between 
R OI levels and cellular Ca 2+ concentrations has been pre- 
v 3usly reported in various systems. Treatment of several dif- 
f¢ rent cell types with H202 induces a considerable increase in 
c, tosolic free calcium [28-30]. This is caused by the release of 
ir ternal stores rather than by the influx of external Ca 2+ be- 
c:use the effect is also seen in the absence of external Ca 2+. 
IqzO2 was shown to access inositol triphosphate-sensitive 
15 ~2+ stores because the oxidant no longer elicits Ca 2+ release 
ir cells which have been depleted of these stores by pretreat- 
rrent with thapsigargin [29]. Interestingly, H202 and O~- gen- 
eJated by the hypoxanthine-xanthine oxidase system were 
s lown to inhibit the ER-resident Ca2+-ATPase in isolated 
E R membranes [31,32]. However, it remains to be determined 
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whether H202 also exerts this effect in vivo. If this is the case, 
this may represent he mechanism by which ROIs mediate 
Ca 2+ release. 
Glucocorticoid-induced apoptosis of thymocytes involves 
both ROI production and a rise in intracellular Ca 2+ [33]. 
Treatment of thymocytes with the antioxidant NAC pre- 
vented both the glucocorticoid-induced rise in intracellular 
Ca 2+ and endonuclease activation. Interestingly, contrary to 
our observation in HeLa cells, in thymocytes pretreatment 
with BAPTA-AM failed to inhibit glucocorticoid-induced oxi- 
dative stress. However, the Ca 2+ chelator quin 2 prevents 
H202-mediated DNA damage and cytotoxicity in thymocytes. 
Thus, many physiological processes require both Ca 2+ and 
ROIs and each of the messengers can perpetuate the produc- 
tion or release of the other in a positive regulatory feedback. 
In order to elucidate the mechanism by which Ca 2+ release 
leads to ROI production, the Ca p-+ responsive ROI-generating 
enzymes need to be identified. 
Here, we have tested a number of compounds that block 
known ROI-generating enzymes. While one inhibitor of cy- 
clooxygenases and lipoxygenases, tepoxalin [34-36], inhibited 
NF-~B activation in response to thapsigargin, a second inhib- 
itor of these enzymes, ETYA, had no effect. This may be 
explained by the different mechanism of action of the two 
inhibitors. Cyclooxygenase-1 (COX-I) is composed of a cy- 
clase and a peroxidase activity. While the arachidonic acid 
analogue EYTA blocks substrate binding, tepoxalin was 
shown to inhibit the peroxidase activity of COX-1 [25,37]. It 
has been shown that tepoxalin does not act as an antioxidant, 
a possibility which must be considered for NF-~cB inhibitors 
[38]. This is consistent with our observation that tepoxalin 
does not inhibit TPA- or TNF-induced NF-~B activation. 
In contrast, a previous study reported that tepoxalin inhibits 
TPA/ionomycin-mediated NF-~B stimulation in HeLa cells 
C~ 
v 
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Thapsigargin (5~.M): - -  - - J r ' - -  - - -{ - - -  - - -{ - - -  - - - -  
CPA (151~M): ~" - - - -"1-  - - - - - I "  - - - -  
PDTC (100~U): "1- -I- 4" -~--- 
BABTA-AM (30~M): "1-'{-'1" --"1" 
Fig. 9. Thapsigargin and CPA stimulation of HeLa cells causes oxi- 
dative stress, which is prevented by preincubation with the Ca 2+ 
chelator BAPTA-AM. HeLa cells were pretreated for 1 h with 
either 100 p.M PDTC or 30 btM BAPTA-AM as indicated. Cells 
were subsequently stimulated for 1 h with either 250 btM H20~, 15 
btM thapsigargin or 75 ~tM CPA. Cells were harvested in PBS as in- 
cubated with 5 IiM of the flourescent dye DCFH for 10 min at 
37°C. Cells were subjected to FACS analysis. Mean flourescence as 
a percent of untreated control cells is depicted. The experiment was 
performed four times with similar results. The average of two inde- 
pendent experiments is shown. 
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and slightly reduces TNF-mediated activation [38]. However, 
the effect on TNF-mediated induction was very small and 
non-specific binding was also decreased by tepoxalin treat- 
ment. We therefore submit that tepoxalin does not affect 
TNF-mediated NF-~B activation in HeLa cells. We also ob- 
served no effect of tepoxalin on TPA-mediated NF-~cB stimu- 
lation. We cannot compare this result to the inhibition of 
TPA/ionomycin-induced activation reported by Kazmi et al. 
[38] since different stimuli and cells were used. However, it is 
interesting to speculate that tepoxalin may specifically inter- 
fere with Ca2+-mediated NF-~cB activation as induced by 
thapsigargin and ionophore treatment. The fact that Kazmi 
et al. did not observe any inhibition of PMA/ionophore 
mediated NF-~cB stimulation by treatment with the cyclooxy- 
genase inhibitor naproxen, the lipoxygenase inhibitor zileuton 
or a combination of both agents upports the idea that tepox- 
alin is selectively targeting the enzyme's peroxidase moiety. 
The transcription factor dorsal, a NF-KB homologue, is 
responsible for the generation of dorso-ventral polarity in 
the fruitfly Drosophila melanogaster. Like NF-~B, dorsal is 
retained in an inactive cytoplasmic form by binding of an 
inhibitor protein, the IKB homologue cactus. It was recently 
shown that an increase of intracellular Ca 2+ causes nuclear 
localization of transfected orsal protein in Schneider cells 
[39]. It remains to be investigated whether Ca 2+ also mediates 
this effect in the Drosophila embryo. However, it appears that 
Ca 2+ may serve a more important role in NF-~B activation 
than previously recognized. 
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